SCHEMBL10124190

SCHEMBL10124190

Fc1ccc(-n2ncc3ncccc32)cc1Cl

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP17A1 P05093 1/20 0.44
CYP1A2 P05177 1/20 0.44
ALDH1A1 P00352 2/20 0.41
ESR1 P03372 1/20 0.41
POLB P06746 1/20 0.41
HPGD P15428 1/20 0.41
GRIN1 Q05586 3/20 0.40
GRIN2B Q13224 3/20 0.40
RXRA P19793 1/20 0.40
NR3C1 P04150 1/20 0.40
IDO1 P14902 1/20 0.39
TDO2 P48775 1/20 0.39
PDE4B Q07343 2/20 0.39
PDE4D Q08499 2/20 0.39
RPS6KA5 O75582 2/20 0.39
GRM4 Q14833 1/20 0.38
EGFR P00533 1/20 0.36
KDR P35968 1/20 0.36
MAPK1 P28482 2/20 0.36
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2361171 0.82 GRIN1 (0.45) CYP17A1CYP1A2ALDH1A1GRIN1GRIN2B
SCHEMBL10124073 0.79 CYP17A1 (0.49) CYP17A1CYP1A2GRIN1GRIN2BNR3C1
SCHEMBL2360174 0.79 NR3C1 (0.46) CYP17A1CYP1A2ALDH1A1ESR1POLB
SCHEMBL15491624 0.71 CYP17A1 (0.46) CYP17A1CYP1A2GRIN1GRIN2BPDE4B
SCHEMBL361292 0.68 CYP17A1 (0.61) CYP17A1CYP1A2NPC1MAPTRAB9A
SCHEMBL19100862 0.67 RPS6KA5 (0.58) RPS6KA5RAB9A
SCHEMBL19259088 0.67 PDE10A (0.45) GRIN1GRIN2BRPS6KA5
SCHEMBL15331211 0.66 ALDH1A1 (0.43) CYP17A1CYP1A2ALDH1A1ESR1POLB
SCHEMBL25340505 0.65 NR3C1 (0.36) CYP17A1CYP1A2NR3C1RPS6KA5MAPK1
SCHEMBL13790417 0.65 XDH (0.59) CYP17A1CYP1A2ALDH1A1HPGDEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2655371-B1 PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INT (DE) 2015-02-25 EP disclosed
US-8546442-B2 Pyrazolopiperidine compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-8546442-B2 Pyrazolopiperidine compounds as CCR1 receptor antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2013-10-01 US disclosed
US-20120322790-A1 Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-20 US disclosed
US-20120322790-A1 Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-12-20 US disclosed
WO-2012087782-A1 PYRAZOLOPIPERIDINE COMPOUNDS AS CCR1 RECEPTOR ANTAGONISTS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120322790-A1 Pyrazolopiperidine Compounds As CCR1 Receptor Antagonists CCR1, CCR3, CCR4 CYP17A1 2315/4885CYP1A2 1866/4885ALDH1A1 719/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.